Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1

Conditions

Breast Neoplasms 8Ovarian Neoplasms 6Neoplasm Metastasis 4Advanced Solid Tumors 4Triple Negative Breast Neoplasms 3Small Cell Lung Carcinoma 3Prostatic Neoplasms 3Leukemia, Myeloid, Acute 3Fallopian Tube Neoplasms 3Pancreatic Neoplasms 2Neoplasms 2Colorectal Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Vaginal Neoplasms 1Uterine Cervical Neoplasms 1Triple Negative Metastatic Breast Cancer 1Thrombocythemia, Essential 1Stomach Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Solid Tumor 1Sarcoma, Ewing 1Primary Myelofibrosis 1Polycythemia Vera 1Neuroendocrine Tumors 1Myeloproliferative Disorders 1Myelodysplastic Syndromes 1Metastatic Castration Resistant Prostate Cancer (mCRPC) 1Mesothelioma 1Lymphoma, Mantle-Cell 1Lung Neoplasms 1

Interventions

Decitabine 4Cyclophosphamide 4ruxolitinib 3fludarabine phosphate 3Filgrastim 3Etoposide 3Topotecan 2Tacrolimus 2Peripheral Blood Stem Cell Transplantation 2Methylprednisolone 2LY2784544 2Cytarabine 2Carboplatin 2Antilymphocyte Serum 2veliparib 1umbralisib 1tipifarnib 1talazoparib 1spartalizumab 1sonidegib 1sargramostim 1sabatolimab 1romidepsin 1pyroxamide 1peginterferon alfa-2a 1nelarabine 1navitoclax 1fresolimumab 1durvalumab 1arsenous acid 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Polycythemia Vera × talazoparib × Clear all
NCT06218628 2024-05-03

Pacritinib w/ Talazoparib in Pts w/ Myeloproliferative Neoplasms Unresponsive to JAK2 Inhibition

Fox Chase Cancer Center

Phase 1 Recruiting
24 enrolled
MyeloidOther hematologic neoplasm

Myeloproliferative Disorders, Polycythemia Vera, Thrombocythemia, Essential, Leukemia, Myelomonocytic, Chronic, Primary Myelofibrosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡